A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma

Shanghai University of Traditional Chinese Medicine240 enrolled

Overview

Investigators aimed to assess Jia Wei Yang He Formula as a plus therapy in the treatment of persistent asthma and to explore Airway Microbiome variation of Asthma by Traditional Chinese Medicine treatment

Asthma is a common chronic inflammatory respiratory disease, patients showed high airway reactivity, and the clinical manifestations of recurrent wheezing, shortness of breath, chest tightness or cough with wheezing dyspnea mainly for a breath. Although many studies have shown that viral infections may be an important cause of asthma seasonal attacks. However, more and more studies have shown that bacterial infection is an important risk factor for asthma. Haemophilus influenzae, Moraxella Mora bacteria infection may increase the risk of asthma by a research report. Chinese medicine decoction, as a common treatment for asthma, can significantly alleviate seasonal attacks and reduce the number of acute attacks. Research shows that Chinese medicine has widely immunomodulatory effects and imbalance of immune system in patients with asthma control, improve the cellular immunity of patients with airway and defense function, significantly reduced asthma attacks of which induced by upper airway infection or chronic persist asthma. This study will be conducted for 4 weeks of standard anti-asthma treatment plus Jia Wei Yang He Formula for patients.Some patients are not willing to use standard treatment such as inhaled corticosteroids and long-acting β-adrenoceptor agonists because of side effects. We will provide these patients free JWYH formula after the efficacy of the JWYH is validated and the subsequent results are considered exploratory. Participants will undergo a physical examination, lung function, blood and sputum collection and all induced sputum samples will be detected by 16S ribosomal RNA (16S rRNA) sequencing and analyzed for microbial bioinformatics. To study whether there is association between the efficacy of Jia Wei Yang He Formula and the changes in microbiota composition.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

240

Conditions

Bronchial Asthma

Interventions

Jia Wei Yang He granuleDRUG

This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time

Jia Wei Yang He granule PlaceboDRUG

Made from 1/20 doses which has certain taste, but no therapeutic effect

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient diagnosed with chronic persistent asthma * Annual uncontrollable time ≥ 3 months * Patients who have given written informed consent Exclusion Criteria: * History of upper upper/lower respiratory infection in the previous 1 months * History of long-term controller medication use for asthma (oral corticosteroid or intravenous corticosteroids therapy) within the preceding 1 months * History of antibiotic use in the previous 1 months * History of life-threatening asthma * History of chronic lung diseases other than asthma, including but not limited to chronic obstructive pulmonary disease, bronchiectasis, emphysema, tuberculosis, sarcoidosis, pulmonary fibrosis, lung cancer, etc * History of serious disease of the heart and cerebrovascular disease * History of severe liver or renal dysfunction or disease * History of severe disease in the hematopoietic system * History of immunodeficiency (including, but not limited to, HIV positive detection, or other acquired or congenital immunodeficiency disease, or organ transplant history) * History of any other condition (such as known drug or alcohol abuse or psychiatric disorder) which, in the opinion of the investigator, may preclude the patient from following and completing the protocol * Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study * History of allergies to the component of the investigated drugs * Smoking within the past year * Contraindication to induced sputum collection method on history or examination * Any serious medical condition which, in the opinion of the Investigator, would pose a significant risk to the patient or interfere with the interpretation of safety, efficacy, or pharmacodynamic data

Locations (8)

Longhua Hospital Affiliated Shanghai University of TCM

Shanghai, Shanghai Municipality, China

RECRUITING

Fengxian District traditional Chinese medicine hospital

Shanghai, China

NOT_YET_RECRUITING

Jingan district center hospital

Shanghai, China

Outcomes

Primary Outcomes

Asthma Control Test Score variation

Measured the change from Baseline to the end of treatment

Time frame: Baseline and 4 weeks

Secondary Outcomes

Airway microbial diversity

Measured by 16S rRNA sequencing of induces sputum

Time frame: Baseline, 2 weeks and 4weeks

Pulmonary function tests

Measured the change from Baseline to the end of treatment

Time frame: Baseline and 4 weeks

Fractional exhaled nitric oxide (FeNO)

Measured the change from Baseline to the end of treatment of exhaled nitric oxide

Time frame: Baseline and 4 weeks

Morning and evening Peak Expiratory Flow (PEF)

Measured the change from Baseline to the end of treatment

Time frame: Measured during the 4 weeks treatment period

Cytokine levels of serum

Measured the change from Baseline to the end of treatment

Time frame: Baseline and 4 weeks

Central Contacts

Zifeng Ma, Master

CONTACT

+8621-64385700 mzf05@126.com

Zhenhui Lu, Doctor

CONTACT

+8621-64385700 tcmdoctorlu@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.